Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GE, GSK partner to develop genetic oncology testing service

GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with  GE Healthcare  to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.

GlaxoSmithKline deepens its commitment to 'electroceuticals'

GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.

ESMO: The latest skinny on drugs from Pfizer, Novartis, GSK, Merck, BMS

The European Society for Medical Oncology meeting may not be as enormous as its U.S. counterpart, but plenty of news is flowing. And some of the new data presented in Madrid over the weekend is pretty dramatic.

ESMO: Bristol-Myers, Roche, AstraZeneca, GSK, Merck jostle for spotlight

Over the weekend oncology investigators from all around the world gathered in Madrid at the European Society for Medical Oncology (ESMO) 2014 Congress to review the latest advances--and setbacks--in the fast-moving field of cancer drug research. As usual, the big companies dominated the discussions, as rival oncology groups touted new data as they tried to position competing therapies in the global scramble to develop new and better cancer drugs, now one of the hottest fields in R&D.

Thermo Fisher to develop 'universal' oncology companion diagnostic with GSK, Pfizer

Diagnostics giant Thermo Fisher Scientific has partnered with GlaxoSmithKline and Pfizer to create a companion diagnostic for solid tumors that will address multiple drug programs. The move is a first step to superseding the often highly fragmented development and use of companion diagnostics to determine the best course of treatment for a particular patient.

Hail GSK's chairman-to-be Philip Hampton: It's a tough job ahead

It's official: GlaxoSmithKline tapped Royal Bank of Scotland chair Philip Hampton to take the reins as chairman.

Accidental poliovirus dump adds to GSK's production woes

Having begun the month by revealing new problems at its Canadian flu vaccine plant and followed that up with a fine for violating the U.S. Clean Air Act last week, GSK has now accidentally dumped live poliovirus into the Belgian sewer system.

Adaptimmune gathers $104M to fuel hot immuno-oncology tech race

A slate of top-tier biotech investors are coming in with a whopping $104 million Series A designed to take Oxford-based Adaptimmune--named a Fierce 15 company earlier in the week--well down the clinical path on its immuno-oncology tech.

GlaxoSmithKline soon to name RBS chair Hampton as next chairman

The folks looking for a switcheroo at the top of GlaxoSmithKline may get their wish by the weekend. Sources tell Sky News that GSK is set to name a new chairman to replace Christopher Gent: Philip Hampton, now chairman at Royal Bank of Scotland and a widely reported frontrunner for the GSK job.

GSK says risk is low from vaccine-contaminated water released into Belgian river

GlaxoSmithKline has been working with Belgian officials after "human error," resulted in 45 liters of cleaning liquid contaminated with poliovirus to get dumped into a city sewer system and subsequently into the Lasne River.